127 Views

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC

Sunday, November 6, 2022

Location: On-Demand

CE: .75 credit/contact hour

Speaker(s)

Explain the evidence base underlying recent FDA drug approvals and important updates to clinical practice guidelines leading to new molecular targeted therapies for patients with mNSCLC.
Describe relevant data from recent clinical trials of emerging biomarkers and their matching targeted therapies for patients with mNSCLC.
Employ best practices for monitoring and managing side effects associated with molecular targeted therapies for patients with mNSCLC.